Compugen Ltd.

NasdaqCM:CGEN Stock Report

Market Cap: US$137.0m

Compugen Management

Management criteria checks 3/4

Compugen's CEO is Anat Cohen-Dayag, appointed in Jun 2009, has a tenure of 15.5 years. total yearly compensation is $1.46M, comprised of 32.7% salary and 67.3% bonuses, including company stock and options. directly owns 0.063% of the company’s shares, worth $85.87K. The average tenure of the management team and the board of directors is 5.1 years and 7.5 years respectively.

Key information

Anat Cohen-Dayag

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage32.7%
CEO tenure15.5yrs
CEO ownership0.06%
Management average tenure5.1yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Aug 22
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

May 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

May 01
Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Apr 05
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 08
Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Feb 17
Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Oct 10
Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Jun 22
Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Sep 21
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen appoints Alberto Sessa as CFO

Sep 12

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Aug 24

Compugen Q2 2022 Earnings Preview

Aug 03

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Jun 23
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Mar 02
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Aug 27
Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Jun 28
Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Compugen gains on takeover speculation after iTeos Therapeutics deal

Jun 14

Compugen reports updated COM701 data from Phase 1 study at ASCO21

Jun 08

Compugen's COM902 demonstrates potential benefit in cancer

Apr 27

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 15
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

Feb 08
Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Jan 04
A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Compugen earns $2M milestone under antibody development deal with AstraZeneca

Dec 23

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 30
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

CEO Compensation Analysis

How has Anat Cohen-Dayag's remuneration changed compared to Compugen's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$2m

Jun 30 2024n/an/a

-US$10m

Mar 31 2024n/an/a

-US$17m

Dec 31 2023US$1mUS$479k

-US$19m

Sep 30 2023n/an/a

-US$32m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$1mUS$479k

-US$34m

Sep 30 2022n/an/a

-US$39m

Jun 30 2022n/an/a

-US$34m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$1mUS$498k

-US$34m

Sep 30 2021n/an/a

-US$34m

Jun 30 2021n/an/a

-US$36m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$1mUS$453k

-US$30m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$26m

Dec 31 2019US$941kUS$395k

-US$27m

Sep 30 2019n/an/a

-US$30m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$31m

Dec 31 2018US$854kUS$391k

-US$23m

Sep 30 2018n/an/a

-US$23m

Jun 30 2018n/an/a

-US$29m

Mar 31 2018n/an/a

-US$28m

Dec 31 2017US$740kUS$392k

-US$37m

Compensation vs Market: Anat's total compensation ($USD1.46M) is above average for companies of similar size in the US market ($USD654.40K).

Compensation vs Earnings: Anat's compensation has been consistent with company performance over the past year.

CEO

Anat Cohen-Dayag (57 yo)

15.5yrs

Tenure

US$1,464,448

Compensation

Dr. Anat Cohen-Dayag, Ph D., served as an Independent Director at Gamida Cell Ltd since January 28, 2022 until March 2023. She serves as Director at has been Chief Executive Officer and President at Compug...

Leadership Team

NamePositionTenureCompensationOwnership
Anat Cohen-Dayag
CEO, President & Director15.5yrsUS$1.46m0.063%
$ 85.9k
Eran Ophir
Chief Scientific Officer4.8yrsUS$540.64kno data
Zurit Levine
Senior Vice President of Technology Innovation6.9yrsUS$532.26kno data
Pierre Ferre
Vice President of Preclinical Development3.7yrsUS$570.40kno data
David Silberman
Chief Financial Officerless than a yearno datano data
Yvonne Naughton
Head of Investor Relations & Corporate Communicationsno datano datano data
Eran Dor
General Counsel & Corporate Secretary5.9yrsno datano data
Dorit Amitay
Vice President of Human Resources17.9yrsno datano data
Yaron Turpaz
Senior VP & Senior Advisor of Data and Informatics Solutions5.1yrsno datano data
Rivka Schwartz
Vice President Research and Discoveryno datano datano data
Michelle Mahler
Chief Medical Officerless than a yearno datano data

5.1yrs

Average Tenure

53yo

Average Age

Experienced Management: CGEN's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Anat Cohen-Dayag
CEO, President & Director10.8yrsUS$1.46m0.063%
$ 85.9k
Nils Lonberg
Member of Scientific Advisory Board4.3yrsno datano data
Sanford Zweifach
Independent Director6.5yrsno datano data
Howard Soule
Member of Scientific Advisory Board11.3yrsno datano data
Gilead Halevy
Independent Director6.5yrsno datano data
Paul Sekhri
Independent Chairman of the Board7.2yrsno datano data
Kinneret Livnat-Savitzky
Independent Director6.5yrsno datano data
Andrew Pardoll
Chairman of Scientific Advisory Board10.9yrsno datano data
Antoni Ribas
Member of Scientific Advisory Board11.3yrsno datano data
Eran Perry
Independent Director5.4yrsno datano data
Iain McInnes
Member of Scientific Advisory Board11.3yrsno datano data
Miriam Merad
Member of Scientific Advisory Board7.8yrsno datano data

7.5yrs

Average Tenure

58yo

Average Age

Experienced Board: CGEN's board of directors are considered experienced (7.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 00:50
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Compugen Ltd. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Varun KumarCantor Fitzgerald & Co.
Ling WangChardan Capital Markets, LLC
Vernon BernardinoFBR Capital Markets & Co.